Europe Leukapheresis Market Drivers and Forecasts by 2028

The leukapheresis market in Europe is expected to grow from US$ 22.55 million in 2021 to US$ 39.26 million by 2028; it is estimated to grow at a CAGR of 8.2% from 2021 to 2028.

Blood transfusion is an integral part of the national health infrastructure and policies of various countries. Advancements in the medical industry have led to improvements in the treatment procedures of serious illnesses and injuries, which eventually has propelled the need for blood transfusion for patients’ survival. Growing awareness regarding the importance of blood transfusion and blood availability in healthcare services has led to rise in the number of people willing to donate their blood for medical causes. As per the World Health Organization (WHO) data, ~117.4 million blood donations were reported worldwide in 2018. Blood donors are usually classified to be voluntary unpaid, paid, and family/replacement, and as per the WHO claims, voluntary/unpaid donors are the major source of a reliable and adequate supply of blood. According to WHO data in 2019, blood donations by voluntary unpaid donors increased by 11.6 million from 2008 to 2015 in 139 countries in the world. The trend of blood donation is also gaining significant prominence in low and middle-income countries. According to the data presented during the CAG annual meeting 2017, ~13,000 procedures were performed on 1,087 patients in 2016. National programs developed and rolled out in many countries are further attracting a large number of platelet and blood donors. Thus, the rising number of eligible donors in different countries across the world is fostering the need for leukapheresis equipment that is used to separate the required blood components.

The European economy is severely affected due to the exponential growth of COVID-19 cases in the region. Russia, Spain, Italy, Germany, France, and the UK are among the most affected European countries. Countries across Europe are witnessing a resurgence in COVID-19 cases after successfully mitigating outbreaks early in the year. Many countries are declaring more cases each day now than they were during the first wave earlier this year. Lockdowns are being reintroduced in UK, Spain, Italy, and Ireland, as per the European Centre for Disease Prevention and Control (ECDC). Due to the second wave of COVID-19 cases, the government of many countries is working towards scaling up testing capacity, which is driving the growth of the market.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe leukapheresis market. The Europe leukapheresis market is expected to grow at a good CAGR during the forecast period.

Europe Leukapheresis Market Segmentation

 

Europe Leukapheresis Market – By Product Type

• Leukapheresis Disposables
• Leukapheresis Devices

Europe Leukapheresis Market – By Application

• Research Applications
• Therapeutic Applications

Europe Leukapheresis Market – By Product Type

• Blood Component Providers and Blood Centers
• Hospitals and Transfusion Centers
• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes

Europe Leukapheresis Market – By Country

• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Europe Leukapheresis Market – Companies Mentioned

• Asahi Kasei Corporation                                 
• Fresenius SE & Co. KGaA                                
• Haemonetics Corporation                              
• Terumo Corporation                                        
• STEMCELL Technologies Inc.                          
• HemaCare  
• Macopharma
• AllCells
• STEMEXPRESS  
• BioIVT            

Europe Leukapheresis Report Scope